Improved Synthesis of 6-Chloro-5-methylpyridin-2-amine: A Key Intermediate for Making Lumacaftor

Author:

Zhang Junchi12,Zhu Fuqiang3ORCID,Tian Guanghui3,Jiang Xiangrui12ORCID,Shen Jingshan12ORCID

Affiliation:

1. CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zuchongzhi Road, Shanghai 201203, People’s Republic of China

2. University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, People’s Republic of China

3. Topharman Shanghai Co., Ltd., Building 1, No. 388 Jialilue Road, Zhangjiang Hitech Park, Shanghai 201203, People’s Republic of China

Funder

Chinese Academy of Sciences

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Reference21 articles.

1. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

2. Orkambi (lumacaftor/ivacaftor) Oral Tablet: Drug approval by FDA. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/0206038Orig1s000TOC.cfm (accessed 2020-04-24).

3. Cystic fibrosis

4. Orkambi (lumacaftor/ivacaftor) Oral Tablet: Drug approval by EMA. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orkambi_en.pdf (accessed 2020-04-24).

5. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3